| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(E)-3-(4-Methoxyphenyl)acrylic acid has multiple biological targets and activities. It exhibits significant hepatoprotective activity, anti-amnesia effects, enhanced cognitive activity, hypoglycemic effects, and neuro-protection activity. Its mechanisms of action may involve modulation of oxidative stress, inflammation, and metabolic pathways, though specific molecular targets are not definitively identified.
|
|---|---|
| ln Vitro |
In vitro, (E)-3-(4-Methoxyphenyl)acrylic acid demonstrates significant hepatoprotective activity, protecting liver cells from damage. It also shows anti-amnesic, cognition-enhancing, antihyperglycemic, and neuroprotective activities in various in vitro assays. These activities suggest it may modulate oxidative stress, inflammatory responses, and neuronal signaling pathways.
|
| ln Vivo |
In vivo, (E)-3-(4-Methoxyphenyl)acrylic acid exhibits significant hepatoprotective activity, protecting the liver from injury in animal models. It also demonstrates anti-amnesic effects, enhanced cognitive activity, hypoglycemic effects, and neuro-protection activity. These in vivo activities support its potential therapeutic applications in liver disease, cognitive disorders, diabetes, and neurodegenerative conditions.
|
| Enzyme Assay |
In vitro enzyme assays with (E)-3-(4-Methoxyphenyl)acrylic acid typically involve studying its effects on enzymes involved in oxidative stress, inflammation, or metabolic pathways. Standard assays may measure antioxidant activity (e.g., DPPH radical scavenging), enzyme inhibition (e.g., alpha-glucosidase, acetylcholinesterase), or anti-inflammatory activity (e.g., COX inhibition). These assays help characterize its mechanism of action.
|
| Cell Assay |
In vitro cell culture experiments with (E)-3-(4-Methoxyphenyl)acrylic acid involve treating various cell lines such as hepatocytes, neuronal cells, or immune cells with the compound. Cells are treated at various concentrations for defined periods, and endpoints include cell viability, oxidative stress markers, inflammatory cytokine production, and gene expression analysis. These experiments characterize its cytoprotective and neuroprotective effects.
|
| Animal Protocol |
In vivo animal experiments with (E)-3-(4-Methoxyphenyl)acrylic acid typically involve using rodent models of liver injury, cognitive impairment, diabetes, or neurodegeneration. The compound is administered orally or intraperitoneally at various doses for defined periods. Key endpoints include assessment of liver function (ALT, AST), cognitive performance (behavioral tests), blood glucose levels, and histopathological examination of tissues.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of (E)-3-(4-Methoxyphenyl)acrylic acid have not been extensively characterized. As a small, lipophilic molecule, it is expected to be absorbed from the gastrointestinal tract and distributed throughout the body. It is likely metabolized through phase I and phase II metabolic pathways and excreted in urine and bile. Specific PK parameters such as Cmax, Tmax, AUC, and half-life would need to be determined in future studies.
|
| Toxicity/Toxicokinetics |
(E)-3-(4-Methoxyphenyl)acrylic acid has a low toxicity profile based on its natural occurrence in plants and traditional use. It is not considered a hazardous substance. For research use, standard laboratory safety practices are sufficient. It has a melting point of 173.5°C and is a white to off-white solid. Comprehensive toxicology studies have not been published.
|
| References | |
| Additional Infomation |
4-Methoxycinnamic acid is a methoxycinnamic acid with a single methoxy substituent at the 4-position of the benzene ring. It is functionally related to cinnamic acid. It has been reported in Baccharis subdentata, Scrophularia buergeriana, and other organisms with relevant data. See also: 4-Methoxycinnamic acid (note moved to).
(E)-3-(4-Methoxyphenyl)acrylic acid (4-methoxycinnamic acid) is a natural compound with significant hepatoprotective, anti-amnesic, cognition-enhancing, hypoglycemic, and neuroprotective activities. It can be extracted from various plants including Arachis hypogaea and Scrophularia buergeriana. The compound is not a drug and has no approved therapeutic indications. It is available for laboratory research use only as a tool for studying hepatoprotection, neuroprotection, and metabolic regulation. |
| Molecular Formula |
C10H10O3
|
|---|---|
| Molecular Weight |
178.18
|
| Exact Mass |
178.062
|
| CAS # |
943-89-5
|
| Related CAS # |
7340-42-3 (hydrochloride salt)
|
| PubChem CID |
699414
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
342.6±17.0 °C at 760 mmHg
|
| Melting Point |
173.5ºC
|
| Flash Point |
138.6±14.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
2.36
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)/C=C/C(=O)O
|
| InChi Key |
AFDXODALSZRGIH-QPJJXVBHSA-N
|
| InChi Code |
InChI=1S/C10H10O3/c1-13-9-5-2-8(3-6-9)4-7-10(11)12/h2-7H,1H3,(H,11,12)/b7-4+
|
| Chemical Name |
(E)-3-(4-methoxyphenyl)prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (561.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6123 mL | 28.0615 mL | 56.1230 mL | |
| 5 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL | |
| 10 mM | 0.5612 mL | 2.8062 mL | 5.6123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
